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ABSTRACT
Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in
immunocompromised and occasionally in healthy hosts. Scedosporium spp. is intrinsically resist-
ant to most, L. prolificans to all the antifungal drugs currently approved, raising concerns about
appropriate treatment decisions. High mortality rates of up to 90% underline the need for com-
prehensive diagnostic workup and even more for new, effective antifungal drugs to improve
patient outcome. For a comprehensive analysis, we identified cases of severe Scedosporium spp.
and L. prolificans infections from the literature diagnosed in 2000 or later and the FungiScopeVR
registry. For 208 Scedosporium spp. infections solid organ transplantation (n¼ 58, 27.9%) and for
56 L. prolificans infection underlying malignancy (n¼ 28, 50.0%) were the most prevalent risk fac-
tors. L. prolificans infections frequently presented as fungemia (n¼ 26, 46.4% versus n¼ 12, 5.8%
for Scedosporium spp.). Malignancy, fungemia, CNS and lung involvement predicted worse out-
come for scedosporiosis and lomentosporiosis. Patients treated with voriconazole had a better
overall outcome in both groups compared to treatment with amphotericin B formulations. This
review discusses the epidemiology, prognostic factors, pathogen susceptibility to approved and
investigational antifungals, and treatment strategies of severe infections caused by Scedosporium
spp. and L. prolificans.
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Introduction
Advances in medical care led to increasing numbers of
patients with non-Aspergillus mold infections.
Scedosporiosis is of particular concern due to intrinsic
resistance to antifungal therapy (Douglas et al. 2016).
The most relevant pathogens causing invasive scedo-
sporiosis and lomentosporiosis are Scedosporium apio-
spermum species complex [comprising amongst others S.
apiospermum, S. boydii (traditionally and wrongly thought
to be the teleomorph state of the anamorphic fungus S.
apiospermum)], S. aurantiacum, and Lomentospora prolifi-
cans (formerly Scedosporium prolificans but renamed due
to phylogenetic differences to Scedosporium spp.)
(Lackner et al. 2014). In the absence of effective surveil-
lance systems, data on the incidence of Scedosporium-
and Lomentospora-related infections is scarce and differs
by region (Tintelnot et al. 2009). In Spain, a population-
based survey on clinically relevant fungi identified
Scedosporium spp. as the second most relevant filament-
ous fungus after Aspergillus spp. (Alastruey-Izquierdo
et al. 2013). In Italy, incidence of proven scedosporiosis
was 0.08% among acute leukaemia patients (Caira et al.
2008). For Houston, Texas incidence increased from 0.82
to 1.33 cases per 100,000 inpatient days between 1993
and 2005 (Lamaris et al. 2006).
Patients with compromised immune status are at highest
risk of developing invasive scedosporiosis or lomentosporio-
sis. In particular, those with prolonged neutropenia, solid
organ transplant, and patients with inherited or acquired
immunodeficiency. It has long been recognized that
Scedosporium spp. can also cause severe infections in
immunocompetent hosts, e.g. after near drowning in pol-
luted water and after penetrating trauma (Panackal and
Marr 2004; Katragkou et al. 2007). Clinical presentation
depends on the route of infection and immune status and
ranges from superficial and subcutaneous disease to deep
tissue involvement and dissemination (Ishii et al. 2015;
Daniele et al. 2017). Scedosporium spp. and L. prolificans
infections can involve the central nervous system, in
immunocompetent patients through contiguous spread
from the sinuses, and in immunocompromised patients
through haematogenous spread (Tortorano et al. 2014).
L. prolificans is more prone to cause invasive disease than
Scedosporium species, as it produces conidia in body fluid
and tissue and disseminates through the bloodstream
(Husain et al. 2005; Cooley et al. 2007; Tortorano et al. 2014).
Current treatment guidelines recommend combin-
ation of voriconazole or amphotericin B-based formula-
tions with surgery (Rodrıguez-Tudela et al. 2009;
Tortorano et al. 2014; Lass-Fl€orl and Cuenca-Estrella
2017). Scedosporium spp. is often resistant to amphoter-
icin B-based formulations but susceptible to
posaconazole and voriconazole, whereas L. prolificans is
usually pan-resistant (Cuenca-Estrella et al. 1999;
Carrillo and Guarro 2001; Espinel-Ingroff 2001; Bouza
and Mu~noz 2004; Patterson et al. 2016). Mortality rates
rise up to 90% owing to pathogenicity and limited
treatment options (Blyth et al. 2014).
In this study, we comprehensively review scedospor-
iosis and lomentosporiosis cases selected from relevant
literature and the FungiScopeVR registry, with an
emphasis on assessing predictors of mortality.
Methods
FungiScopeVR is a registry study on rare invasive fungal
diseases (IFD) currently active in 74 countries. Its meth-
odology has been described elsewhere (Seidel et al.
2017). Data of scedosporiosis and lomentosporiosis
cases were extracted and included for analysis.
In addition, we performed an electronic literature
search for case reports in PubMed on August 18, 2017
using the search filter “(Scedospori OR
Pseudallescheri OR Lomentospori) AND ((invasive OR
disseminated OR infection) AND (case OR patient OR
report))”. Articles in English, French, German, Italian,
and Spanish were chosen for further selection. Records
presenting cases of invasive Scedosporium spp. or L.
prolificans infection were selected on the basis of the
title and abstract. Reference lists of the identified
articles were checked for further studies. We chose the
case reports with diagnosis made in 2000 or later, i.e.
after marketing authorization of voriconazole for scedo-
sporiosis and other IFD in 2002, and the compassionate
use of voriconazole in the preceding years (Agatha
et al. 2014). Each report was reviewed for demograph-
ics, fungal pathogens, underlying diseases and risk fac-
tors for IFD, site of infection, signs and symptoms at the
time of diagnosis of IFD (imaging findings, fever, cough,
dyspnoe, neurological signs), antifungal and surgical
therapy from first sign of IFD, susceptibility assessed
according to European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and Clinical &
Laboratory Standards Institute (CLSI) reference method
(Institute CaLaS 2008; The European Committee on
Antimicrobial Susceptibility Testing 2017), clinical out-
come, and autopsy findings. Observation time was
defined from day of first sign of IFD to last
patient contact.
Underlying conditions were selected as follows:
treatment of hematological malignancy,
allogeneic hematopoietic stem cell transplantation
(HSCT), long-term immunosuppression (prolonged use
of corticosteroids, treatment with other recognized
2 D. SEIDEL ET AL.
T cell immunosuppressants, such as cyclosporine, TNF-a
blockers, monoclonal antibodies, inherited severe
immunodeficiency), HIV/AIDS, solid organ transplant-
ation (SOT), cystic fibrosis (CF), diabetes mellitus (DM),
near drowning, surgery, trauma, history of pulmonary
tuberculosis (TB), and others. For each patient the main
risk factor was identified. For example, in a car accident
with traumatic injuries and near drowning, inhalation of
polluted water was chosen as the dominating risk fac-
tor, if the primary site of infection was related to the
near drowning event and not the injuries. In patients
with lung transplant on a background of CF or TB, SOT
would dominate.
Proven and probable IFD were included (De Pauw
et al. 2008). Disseminated infection was defined as a
positive blood culture or infection at 2 non-contigu-
ous sites.
In vitro susceptibility was tested for approved anti-
fungals and the novel orotomide antifungal olorofim
(F901318) that inhibits the dihydroorotate dehydrogen-
ase (Oliver et al. 2016; McCarthy et al. 2017) for eight S.
apiospermum and seven L. prolificans isolates collected
in FungiScopeVR using broth microdilution for filament-
ous fungi according to CLSI document M38-A2 (25).
For comparison analysis, cases were grouped accord-
ing to the causative pathogen: (1) infection due to
Scedosporium species including S. apiospermum, S. boy-
dii and S. aurantiacum and (2) infection due to L. prolifi-
cans together with one case that had a mixed infection
with S. apiospermum (Lackner et al. 2014).
Statistical analyses were performed using SPSS 25
(IBM Corp., USA). Characteristics of the patient popula-
tion were compared by calculating the frequencies,
means and medians. For the comparison analysis, Chi2,
Fisher’s Exact Test or t-test were used as appropriate.
Kaplan–Meier method was used to estimate survival
and curves were compared statistically using the log
rank test. The p value 0.05 was considered statistically
significant. Mean survival of time to death was calcu-
lated using the mean and 95% confidence interval (CI
95%). Minimum inhibitory concentrations (MIC) were
compared by calculating medians.
Results
We identified 273 cases with invasive Scedosporium
spp. and L. prolificans infection, 232 from the literature
and 41 from the FungiScopeVR registry (D’Hondt et al.
2000; Mu~noz et al. 2000; Bhatk and Naseeruddin 2001;
Canet et al. 2001; Greig et al. 2001; Kiraz et al. 2001;
Lavy et al. 2001; Luu et al. 2001; Nguyen 2001; Tirado-
Miranda et al. 2001; Campagnaro et al. 2002; Farina
et al. 2002; Levine et al. 2002; Mellinghoff et al. 2002;
Miele et al. 2002; O’Bryan et al. 2002; Raj and Frost
2002; Safdar et al. 2002; Talbot et al. 2002; Taylor et al.
2002; Wu et al. 2002; Zaas 2002; Bosma et al. 2003;
Chaveiro et al. 2003; Fernandez-Mosteirın et al.
2003; Fietz et al. 2003; Gosbell et al. 2003; Horre et al.
2003; Howden et al. 2003; Leck et al. 2003; Nulens et al.
2003; Ochiai et al. 2003; Pennekamp et al. 2003;
Posteraro et al. 2003; Saracli et al. 2003; Ahmed et al.
2004; Danaher and Walter 2004; Figueroa et al. 2004;
German et al. 2004; Kanafani et al. 2004; Kowacs et al.
2004; Perlroth and Miller 2004; Reimann et al. 2004;
Riddell et al. 2004; Shand et al. 2004; Shu et al. 2004;
Tan et al. 2004; Thiagalingam et al. 2004; Larocco and
Barron 2005; O’Doherty et al. 2005; Schaenman et al.
2005; Singh and McCluskey 2005; Uenotsuchi et al.
2005; Vagefi et al. 2005; Verghese et al. 2005; Bates and
Mims 2006; Buzina et al. 2006; Farina et al. 2006; Musk
et al. 2006; Porte et al. 2006; Symoens et al. 2006;
Tascini et al. 2006; Abgrall et al. 2007; Baumgartner
et al. 2007; Bhat et al. 2007; Chen et al. 2007; Jain et al.
2007; Kooijman et al. 2007; Lainscak et al. 2007;
Leechawengwongs et al. 2007; Oh et al. 2007; Pellon
Daben et al. 2007; Rogasi et al. 2007; Sahi et al. 2007;
Sarvat and Sarria 2007; Shankar et al. 2007; Tong et al.
2007; Ananda-Rajah et al. 2008; Guignard et al. 2008; Li
et al. 2008; Mesfin et al. 2008; Nochez et al. 2008;
Satirapoj et al. 2008; Bibashi et al. 2009; Cardoso et al.
2009; Carod-Artal et al. 2009; Chanqueo et al. 2009; Elm
et al. 2009; Ezzedine et al. 2009; Foo et al. 2009; Garcıa-
Vidal et al. 2009; Grenouillet et al. 2009; Horre and
Marklein 2009; Ikewaki et al. 2009; Matsumoto et al.
2009; Morales et al. 2009; Ngai et al. 2009; Sheu et al.
2009; Ahmad et al. 2010; Al-Jehani et al. 2010; Azofra
et al. 2010; Baradkar et al. 2010; Beier et al. 2010;
Gelabert-Gonzalez et al. 2010; Kimura et al. 2010; Morio
et al. 2010; O’Hearn et al. 2010; Ortmann et al. 2010;
Sarva et al. 2010; Sireesha et al. 2010; Spanevello et al.
2010; Fernandez Guerrero et al. 2011; Gottesman-
Yekutieli et al. 2011; Lackner et al. 2011; Luijk et al.
2011; Makino et al. 2011; Nakamura et al. 2011; Nguyen
and Raychaudhuri 2011; Ohashi et al. 2011; Ong et al.
2011; Rivier et al. 2011; Ruinemans et al. 2011; Sole
2011; Stur-Hofmann et al. 2011; Takeuchi et al. 2011;
Tammer et al. 2011; Bose et al. 2012; Ceccarelli et al.
2012; Cetrulo et al. 2012; Harrison et al. 2012; Mays
et al. 2012; Yoneda et al. 2012; Allen et al. 2013; Ergin
et al. 2013; Fadzillah et al. 2013; Henao-Martınez et al.
2013; Holmes et al. 2013; Husain et al. 2013; Kubisiak-
Rzepczyk et al. 2013; Larbcharoensub et al. 2013; Lin
et al. 2013; Nakamura et al. 2013; Sayah et al. 2013;
Slone et al. 2013; Wilson and Kennedy 2013; Yu et al.
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2013; Agatha et al. 2014, Abela et al. 2018; Campa-
Thompson et al. 2014; Kepez Yildiz et al. 2014; Moloney
and Park 2014; Nishimori et al. 2014; Shimizu et al.
2014; Trubiano et al. 2014; Uno et al. 2014; Alpaydın
et al. 2015; Boyce and Collins 2015; Clement et al. 2015;
Cruz et al. 2015; He et al. 2015; Ishii et al. 2015; Kim
et al. 2015; Ochi et al. 2015; Patel et al. 2015; Patel and
Orlandi 2015; Sharma and Singh 2015; Smita et al. 2015;
Strunk et al. 2015; Thomson et al. 2015; Balandin et al.
2016; Bui and Carvounis 2016; Chen et al. 2016; Denton
et al. 2016; Goldman et al. 2016; Guber et al. 2016; Kelly
et al. 2016; Kite and Heng 2016; Lahmer et al. 2016;
Leek et al. 2016; Mohan and Gopakumar 2016; Ogawa
et al. 2016; Roy et al. 2016; Tamaki et al. 2016;
Tilakaratne et al. 2016; Wang et al. 2016; Williams et al.
2016; Ghosh et al. 2017; Hu and Chen 2017; Jain et al.
2017; Kim et al. 2017; Masukane et al. 2017; Mei et al.
2017; Signore et al. 2017; Stoneham et al. 2017; Toth
et al. 2017; Tsuji et al. 2017). Five cases were already
included in the comprehensive review of 162
Scedosporium (Lomentospora) prolificans infections by
Rodrıguez-Tudela et al. (2009) (Greig et al. 2001; Taylor
et al. 2002; Gosbell et al. 2003; Howden et al. 2003;
Singh and McCluskey 2005). Nine cases with unknown
species were omitted from further analysis. Distribution
and reported cases per million population by the coun-
try are given in Figure 1(A,B).
Scedosporium spp.
IFD due to Scedosporium spp. was reported in 208
patients. Five patients had mixed infection, four with
Aspergillus spp., one with Candida spp. The majority
were proven IFD (n¼ 183, 88%). Median age at diagno-
sis was 56 years (IQR 39–65 years), 128 (61.5%) patients
were males.
Predisposing factors
The most common risk factors in immunocompromised
patients (n¼ 118, 56.7%) were SOT (n¼ 58, 49.2%) and
malignancy (n¼ 29, 24.6%) (Table 1). Concerning solid
organ transplantation, most transplants were kidney or
lung transplants (n¼ 22 each, 37.9%). IFD occurred in
median after 365 days (IQR 98–1460 days) in kidney and
after 82 days (IQR 26–461 days) in lung transplant
patients. Eleven of 13 CF patients received a lung trans-
plant. Regarding patients with underlying malignancy,
most had leukaemia or lymphoma (n¼ 21, 72.4%). In
total, eight (27.6%) patients received allogeneic hem-
atopoietic stem cell transplantation for haematological
malignancy. In 10 (34.5%) patients with underlying
malignancy, neutropenia was reported. Nineteen of 33
(57.6%) patients with DM were immunocompromised
due to SOT, malignancy or other long-term
immunosuppression.
In immunocompetent patients (n¼ 90, 43.3%) sur-
gery or trauma were the most prevalent risk factors
(n¼ 17, 18.9% each). The most frequent traumatic
events were eye lacerations and penetrating injuries.
DM was the sole known risk factor in five patients.
Clinical presentation
Fever at onset of the Scedosporium spp. infection was
reported for 53 (25.5%) patients, similar for immuno-
compromised (30/118, 25.4%) and immunocompetent
(23/90, 25.6%) patients. Fever was most frequent in
HSCT recipients, other patients treated for malignancy
and near drowning victims (62.5%, 42.9% and 50%
respectively) but rarely reported for trauma
patients (5.9%).
Scedosporiosis affected skin, lung, CNS, and eye in
the majority of patients (n¼ 58, 27.9%; n¼ 51, 24.5%;
n¼ 50, 24%; n¼ 47, 22.6%, respectively) (Table 1). Lung
was frequently involved in patients with underlying
malignancy, primarily in HSCT recipients (6/8, 75%) and
near drowning victims (6/12, 50%) (Table 1). Pulmonary
infection was identified in 13 of 24 (54.2%) patients
receiving a lung transplant, but in none of the patients
receiving a kidney or liver transplant. Four of the 51
patients with lung infection presented with cough, five
with dyspnoea, and six with both. Chest pain was
reported for only three immunocompromised patients.
Abnormal computed tomography (CT) findings were
presented for 17 (33.3%) patients with lung infection,
mostly infiltrates, cavities with surrounding infiltrates
and nodular lesions. No difference in imaging
findings of the lung between immunocompetent
(n¼ 5) and immunocompromised (n¼ 12) patients
could be identified.
The CNS was frequently affected in transplant recipi-
ents and near drowning victims. The majority of the
patients with CNS infection showed neurological symp-
toms (27/50, 54%), mostly decreased consciousness,
confusion but also hemiparesis in few cases, and com-
plained about headache (17/50, 34%). Occurrence of
neurological symptoms were similar in immunocompe-
tent and immunocompromised patients, but pain was
reported more frequently in the immunocompetent
group (50% versus 21.4% in immunocompromised
patients). Lesions suggestive of IFD were detected by
magnetic resonance imaging (MRI) in 23 (46%) patients
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with CNS infection and by CT in additional six
(12%) patients.
Eye infections were localized in 28 (59.6%) patients
and were involved in disseminated disease in 13
(27.7%). In additional six (12.7%) patients, infection
affected adjacent sinuses or CNS. For 14 (29.8%)
patients with eye infections, impaired or complete loss
of vision was reported; for 21 (44.7%) pain in the eye
was noted. Whereas impaired vision was reported
slightly more frequently in immunocompromised
patients (35% versus 25.9% in immunocompetent
patients), pain was more frequently addressed in
immunocompetent patients (48% versus 40% in
immunocompromised patients).
0.3 - 0.7
0.1 - 0.3
0.05 - 0.1
0.005 - 0.05
Reported cases per million
0.58
0.15
0.05 - 0.1
0.002 - 0.05
Reported cases per million
(A)
(B)
United States (n=57), Australia, Germany (n=17 each), India (n=16), Japan (n=14), France (n=11), Spain 
(n=10), China, Italy, The Netherlands (n=7 each), South Korea, Turkey (n=5 each), Austria (n=4), Belgium, 
Canada, Thailand (n=3 each), Chile, New Zealand, Portugal, Taiwan, Switzerland, United Kingdom (n=2 
each), Brazil, Finland, Greece, Hungary, Ireland, Israel, Lebanon, Malaysia, Romania, Slovenia (n=1 each). 
Australia (n=14), Japan, United States (n=8 each), Spain (n=7), France, Germany (n=5 each), India, Italy, 
United Kingdom (n=2 each), Brazil, The Netherlands, Poland (n=1 each). 
Figure 1. Geographical distribution of (A) 208 scedosporiosis cases and (B) 56 lomentosporiosis cases identified in the literature
and FungiScopeVR presented as number of cases per million population. United States (n¼ 57), Australia, Germany (n¼ 17 each),
India (n¼ 16), Japan (n¼ 14), France (n¼ 11), Spain (n¼ 10), China, Italy, The Netherlands (n¼ 7 each), South Korea, Turkey
(n¼ 5 each), Austria (n¼ 4), Belgium, Canada, Thailand (n¼ 3 each), Chile, New Zealand, Portugal, Taiwan, Switzerland, United
Kingdom (n¼ 2 each), Brazil, Finland, Greece, Hungary, Ireland, Israel, Lebanon, Malaysia, Romania, Slovenia (n¼ 1 each).
Australia (n¼ 14), Japan, United States (n¼ 8 each), Spain (n¼ 7), France, Germany (n¼ 5 each), India, Italy, United Kingdom
(n¼ 2 each), Brazil, The Netherlands, Poland (n¼ 1 each).
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Disseminated Scedosporium spp. infection was pre-
sent in 31 (26.3%) of the immunocompromised, mainly
in transplant recipients, and 15 (16.7%) of immunocom-
petent patients. Lung, CNS, skin, and eye were the most
frequently involved organs in disseminated disease
overall (n¼ 25, 54.3%; n¼ 22, 47.8%; n¼ 19, 41.3%;
n¼ 13, 28.3%, respectively) (Supplementary Table 1(A)).
In 12 (5.8%) patients with confirmed blood stream
infection, the pathogen was isolated from at least one
other organ (mostly CNS, heart or lung). If infection
affected contiguous organs these were eyes, sinuses
and/or CNS in all but two cases with deep soft tissue
infection with involvement of the bone.
Treatment
All but four patients received antifungal drugs for treat-
ment of scedosporiosis, in median for 90 days (IQR 34 –
217 days) (Table 2). Surgical resection, debridement or
drainage of the infected site was performed in 62
(52.5%) immunocompromised patients and in 57
(63.3%) immunocompetent patients. Most patients with
eye infections underwent vitrectomy, keratoplasty, enu-
cleation or surgical drainage of abscesses (32/47, 68%).
Pulmonary infections were mainly treated with systemic
antifungals (49/51, 96%), eight (15.7%) infections were
managed surgically in addition, of which six had local-
ized disease. Brain lesions were resected or surgically
drained in 15 of 50 (30%) patients, of which eight were
immunocompromised and seven immunocompetent.
The majority of the patients received systemic vori-
conazole, amphotericin B-based formulation (amphoter-
icin B) or itraconazole (65.9%, 30.3%, and 27.4%,
respectively) for treatment of scedosporiosis (Table 2).
The most frequent monotherapies were voriconazole
and itraconazole (Supplementary Table 2). In 31 of 46
(67.4%) patients treated with other than these two first
line antifungals, treatment was switched to voricon-
azole. Switch of any antifungal drug to amphotericin B
was rare. Most patients treated with any combination
therapy, received more than one regimen. In the major-
ity of the cases, voriconazole was co-administered,
mostly with terbinafine or amphotericin B.
Posaconazole was rarely used, never as first line mono-
therapy, but rather as salvage or in combination.
Outcome and presumed prognostic factors
All-cause mortality for each risk group and for dissemi-
nated Scedosporium spp. infection is shown in Table 3.
Table 2. Treatment administered to 208 patients with Scedosporium spp. and 56
L. prolificans infection.
Scedosporium spp. L. prolificans
Antifungal prophylaxis (%) 20 (9.6) 13(23.2)
Posaconazole, voriconazole 7 (35) 10 (76.9)
Othera 13 (65) 3 (23.1)
Antifungal treatment
Antifungal and surgery 117 (56.3) 24 (42.9)
Antifungal 87 (41.8) 31 (55.4)
Surgery 2 (1) –
No treatment 2 (1) 1 (1.8)
Antifungal drugs (%)b
Amphotericin B 63 (30.3) 27 (48.2)
Voriconazole 137 (65.9) 38 (67.9)
Posaconazole 15 (7.2) 8 (14.3)
Itraconazole 57 (27.4) 8 (14.3)
Other azolesc 20 (9.6) 4 (7.1)
Terbinafine 26 (12.5) 22 (39.3)
Echinocandind 22 (10.6) 17 (30.4)
Monotherapy 102 (49) 16 (28.6)
Consecutive monotherapy 53 (25.5) 10 (17.9)
Combination therapy 49 (23.6) 28 (50)
Sequential 30 (61.2) 13 (23.2)
Treatment length overall median days (IQR) 90 (34–217) 21 (5–150)
Observation period median days (IQR) 180 (50.5–374) 49 (6–300)
Observation period if alive 285 (142.5–652.5) 330 (180–603.5)
Observation period if dead 30 (10–98.5) 15 (4.5–35)
aScedosporium spp.: Itraconazole (5), fluconazole (4), amphotericin B (3), caspofungin (1); L. prolificans:
fluconazole (2), itraconazole (1).
bsuperadditive.
cScedosporium spp.: Fluconazole (13), isavuconazole (1), miconazole (3), ketoconazole (4); L. prolificans:
Fluconazole (3), isavuconazole (1).
dScedosporium spp.: Caspofungin (16), micafungin (6); L. prolificans: Caspofungin (11), micafungin (6),
anidulafungin (2).
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Day 42 and overall mortality were higher in immuno-
compromised (22.2% and 43.6% respectively) compared
to immunocompetent patients (14% and 30.7%,
respectively). Mortality in patients with malignancy
(55.2% overall), particularly in HSCT recipients (75%),
was higher than in SOT recipients (39.7%) and other
immunocompromised patients (40%) (Supplementary
Figure 1 (A), Table 3). Disseminated disease was associ-
ated with higher mortality in all risk groups, except
near drowning, where four patients with CNS and lung
or eye infection survived. All 12 patients with fungemia
died and death was mostly attributed to IFD. Overall,
attributable mortality was 76%; results for each risk
group are presented in Supplementary Table 3.
Mean survival time varied depending on the risk
group and dissemination of the infection
(Supplementary Figure 1, Figure 2). HSCT recipients had
a shorter mean survival time of 93 days (CI 95% 30–157)
compared to patients with underlying malignancy with-
out HSCT (236 days, CI 95% 41–156), SOT (271 days, CI
95% 230–312), and other conditions requiring long-
term immunosuppression (220 days, CI 95% 156–283).
Overall, for immunocompromised patients with disse-
minated Scedosporium spp. infection mean survival
time was 156 days (CI 95% 98–214); in the seven
patients with blood stream infection 42 days (CI 95%
0–107). If infection was localized, mean survival time
was 270 days (CI 95% 236–305). In immunocompetent
patients with disseminated disease, mean survival time
was 175 days (CI 95% 87 – 262); in the five patients
with blood stream infection 12 days (CI 95% 5–19). If
infection was localized, mean survival time was
293 days (CI 95% 261–325) accordingly.
Bivariate analysis revealed that in SOT recipients,
infection of the CNS and disseminated infection were
associated with higher mortality (Supplementary Table
4(A)). In patients with underlying malignancy, infection
of the lung predicted worse outcome. This holds true
if HSCT recipients were excluded (Log Rank Test
p¼ 0.011, data not shown). In immunocompromised
patients who developed CNS complications, the 42-day
mortality was higher compared to those with other
infected sites, both in patients with localized (33.3% ver-
sus 15.9%) and disseminated disease (60% versus
18.8%). In immunocompetent patients with
localized infection, CNS involvement was associated
with higher 42-day mortality compared to other
affected organs (23.1% versus 6.5%, Fisher’s Exact Test
p¼ 0.095). No difference in 42-day mortality was identi-
fied in immunocompetent patients with disseminated
disease with versus without CNS involvement (33.3%
versus 33.3%).
Table 3. All-cause mortality overall and at day 42 in patients with Scedosporium spp. (n¼ 205) and L. prolificans
(n¼ 55) infection.
Risk group
Scedosporium spp. (n¼ 205) L. prolificans (n¼ 55)
Events % Events day 42 % Events % Events day 42 %
overall/total overall /total day 42 overall/total overall /total day 42
SOT 23/58 39.7 10/52 19.2 4/7 57.1 2/7 28.6
Localized 5/35 14.3 3/33 9.1 1/3 33 0/3 0
Disseminated 18/23 78.3 7/19 38.9 3/4 75 2/4 50
Malignancy 16/29 55.2 8/26 30.8 24/28 85.7 20/28 71.4
Localized 12/24 50 7/22 31.8 2/4 50 1/4 25
Disseminated 4/5 80 1/4 25 22/24 91.7 19/24 79.2
HSCT 6/8 75 4/8 50 7/9 77.8 6/9 66.7
Localized 4/6 66.7 3/6 50 1/2 50 1/2 50
Disseminated 2/2 100 1/2 50 6/7 85.7 5/7 71.4
Other immunocompromised 12/30 40 6/29 20.7 1/4 25 1/4 25
Localized 10/27 37 5/26 19.2 0/3 0 0/3 0
Disseminated 2/3 66.7 1/3 33.3 1/1 100 1/1 100
Surgery 7/17 41.2 3/16 18.8 2/8 25 1/8 12.5
Localized 3/12 25 1/12 8.3 1/6 16.7 0/6 0
Disseminated 4/5 80 2/4 50 1/2 50 1/2 50
Trauma 2/16 12.5 0/16 0 1/3 33.3 1/3 33.3
Localized 0/14 0 0/14 0 0/3 0 0/3 0
Disseminated 2/2 100 0/2 0 1/1 100 1/1 100
Near drowning 3/12 25 0/12 0 – – – –
Localized 3/8 37.5 0/8 0 – – – –
Disseminated 0/4 0 0/4 0 – – – –
Other immunocompetent 12/28 42.9 6/27 22.2 1/3 33.3 1/3 33.3
Localized 11/26 42.3 5/25 20 0/2 0 0/2 0
Disseminated 1/2 50 1/2 50 1/1 100 1/1 100
Unknown 3/15 20 3/15 20 0/2 0 0/2 0
Localized 1/13 7.7 1/13 7.7 0/2 0 0/2 0
Disseminated 2/2 100 2/2 100 – – – –
SOT: solid organ transplantation; HSCT: allogeneic hematopoietic stem cell transplantation.
Disseminated: positive blood culture or infection at 2 non-contiguous sites.
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Surgical treatment of eye infections was not associ-
ated with better overall survival in this case series. Day
42 mortality was 6.3% (2/32) and 13.3% (2/15) in
patients with and without surgically treated eye infec-
tion, respectively (Fisher’s Exact Test p¼ 0.602). In
patients with and without surgically treated brain infec-
tion, day 42 mortality was 20% (3/15) and 37.1% (13/
35), respectively (Fisher’s Exact Test p¼ 0.328).
Overall, patients who received voriconazole for the
treatment of scedosporiosis had a longer mean survival
time compared to the patients treated with amphoteri-
cin B (276 days, CI 95% 248–304 versus 144 days, CI 95%
78–209) (Supplementary Figure 3(A)). For voriconazole
similar mean survival times were seen in immunocom-
promised and immunocompetent patients (274 days, CI
95% 235–312 versus 280 days, CI 95% 238–321; Log
Rank Test p¼ 0.651), whereas for amphotericin B sur-
vival time was longer in immunocompetent than in
immunocompromised patients (206 days, CI 95%
104–309 versus 95 days, CI 9% 19–170; Log Rank Test
p¼ 0.065).
Day 42 mortality was lower in patients treated with
voriconazole compared to those treated with any for-
mulation of amphotericin B in immunocompromised
(11.3% versus 58.8%, Fisher’s Exact Test p< 0.001) and
immunocompetent (14% versus 23.1%, Fisher’s Exact
Test p¼ 0.416) patients. Treatment with voriconazole
was associated with lower day 42 and overall mortality
in localized and disseminated disease compared to
treatment with amphotericin B.
Antifungal susceptibility
In vitro susceptibility to antifungals was available for
clinical isolates of Scedosporium spp. from 34 patients
(Table 4). Median MIC values were lowest for olorofim
(0.0039mg/L for all isolates), voriconazole (0.5mg/L,
IQR 0.25–1mg/L) and posaconazole (1.5mg/L, IQR
0.25–1mg/L), and high for amphotericin B (12mg/L,
IQR 2.5–16mg/L) and terbinafine (16mg/L, IQR 3 –
32mg/L). Highest MICs were determined for flucon-
azole (24mg/L, IQR 16 – 56mg/L), and flucytosine
(128mg/L for all isolates). In rare cases low MICs
(0.5mg/L) were determined for amphotericin B, itra-
conazole as well as for echinocandins but not for ter-
binafine, fluconazole and flucytosine for which MICs
were >2mg/L for all isolates.
Lomentospora prolificans
Fifty-six patients with L. prolificans infection were identi-
fied. Three had a mixed IFD with additional identifica-
tion of Aspergillus spp., Exserohilum spp. or S.
apiospermum. The majority were proven IFD (n¼ 52,
92.9%). Median age at diagnosis was 58 years (IQR
42–67 years), 32 (57.1%) patients were male.
Predisposing factors
Of 56 patients with L. prolificans infection, the majority
were immunocompromised (n¼ 39, 69.6%), most
related to an underlying malignancy (n¼ 28, 71.8%) or
a SOT (n¼ 7, 17.9%) (Table 1). Leukaemia and lymph-
oma were the most frequent haematological diseases
(n¼ 19, 67.9% and n¼ 4, 14.3%). Nine (32.1%) patients
received HSCT and overall, for 13 (46.4%) patients neu-
tropenia during treatment of the underlying malig-
nancy was reported. Transplant patients had received a
lung (n¼ 4), kidney (n¼ 2) or heart (n¼ 1).
Lomentosporiosis was reported in 17 immunocompe-
tent patients, mainly in surgical and trauma patients
(n¼ 7, 41.2% and n¼ 5, 29.4%, respectively).
Clinical presentation
Fever was present before diagnosis of L. prolificans
infection in 41% (16/39) of immunocompromised
patients, mostly those with malignancy (15/28, 53.7%),
Table 4. Median minimum inhibitory concentrations in Scedosporium spp. and L. prolificans clinical isolates assessed using the
EUCAST and CLSI procedures.
Scedosporium spp. L. prolificans
n MIC Median (IQR) mg/L n MIC Median (IQR) mg/L
Amphotericin B 28 12 (2.5–16) 18 16 (4–16)
Flucytosine 7 128 .a 8 128 (80–128)
Terbinafine 5 16 (3–32) – – –
Fluconazole 10 24 (16–56) 8 128 (128–224)
Isavuconazole 8 3 (1.3–13) 7 32 .a
Itraconazole 18 2 (1–16) 11 16 (16–32)
Posaconazole 21 1.5 (0.5–2) 10 32 (28–32)
Voriconazole 32 0.5 (0.3–1) 17 8 (6–16)
Caspofungin 10 3 (1.6–10) – – –
Micafungin – – – 6 24 (0.9–32)
F901318 8 0.0039 .a 7 0.0039 .a
asame MIC in all isolates tested.
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and in 29.4% (5/17) of immunocompetent patients,
mostly surgical patients (4/7, 57.1%). In none of the
patients with traumatic injuries, long-term immunosup-
pression and in only one kidney transplanted patient
fever was reported before diagnosis of IFD.
L. prolificans infection most frequently affected lung,
eye, and heart (n¼ 22, 39.3%; n¼ 12, 21.4%; n¼ 11,
19.6%, respectively). Ten of 11 patients with infection of
the heart had disseminated disease, seven with positive
blood culture. Disseminated infection was more fre-
quent in immunocompromised patients (n¼ 29, 74.4%
versus n¼ 4, 23.5% of immunocompetent patients) and
was mostly associated with fungemia in both groups
(Table 1, Supplementary Table 1). Overall, in 8 of 26 (30.8%)
patients with fungemia, no other infected organ was
reported. In the other 18 fungemia cases as well as in
cases with disseminated infection without reported
blood stream infection (n¼ 7), on average a total of
three affected organs was identified. Here, lung and/or
heart were most frequently reported (Supplementary
Table 1(B)). In 10 (45.5%) patients with lung infections,
radiological signs were seen. CT scans showed mostly
pulmonary areas of nodular consolidation without cavi-
tation and less frequently infiltrates; halo or air-crescent
signs were not reported. For seven (31.8%) patients
with lung infection, dyspnoea or cough was reported.
Eye infections were localized in four (33.3%) patients.
Pain in the eye was reported for four patients, for one
of them and additional three patients, blurred vision
was reported. Infection of the CNS was diagnosed in
immunocompromised patients only (n¼ 6, 10.7%), in
five the infection was disseminated, four with blood
stream infection. Lesions on head MRI and CT scans
were presented for four of these cases.
Overall, L. prolificans infection was localized in 10
(25.6%) immunocompromised patients and 13 (76.5%)
immunocompetent patients; lung (n¼ 8), bone (n¼ 6)
or eye (n¼ 4) were most frequently affected. For four of
eight (50%) patients with localized lung infection, dys-
pnoea or cough before diagnosis was reported.
Treatment
All but one patient with L. prolificans infection received
antifungals for treatment (Table 2). One patient with
disseminated infection received intravitreal injection
only and died after a few days. Nine (23.1%) immuno-
compromised and 15 (88.2%) immunocompetent
patients underwent surgery. Two of 22 lung infections
were treated with lobectomy, both patients were
immunocompetent. Seven of 12 patients with eye
infection underwent vitrectomy or enucleation. None of
the brain infections were operated on.
Antifungals most frequently used for treatment of
lomentosporiosis were voriconazole, amphotericin B,
terbinafine, and echinocandins (67.9%, 48.2%, 39.3%,
and 30.4%, respectively) (Table 2). Median treatment
duration was 21 days (IQR 5–150 days). Sixteen patients
received monotherapy, mostly amphotericin B, voricon-
azole or itraconazole for a median of 11 days (IQR
4–35 days). Two patients with fungemia and treated
with echinocandin monotherapy died within 2 weeks.
Half of the patients received combination therapy,
mostly with voriconazole plus terbinafine or amphoteri-
cin B (Supplementary Table 2) for a median of 35 days
(IQR 15–330 days). In 13 (26%) patients treated with
combination therapy, more than one regime was
administered.
Outcome
Overall mortality, as shown in Table 3 for each risk
group, was higher in immunocompromised than in
immunocompetent patients with L. prolificans infection
(74.4% versus 25%, Fisher’s Exact Test p¼ 0.001), being
highest in patients with malignancy (85.7%), similar for
patients with and without HSCT, and SOT (57.1%)
(Supplementary Figure 1(B), Table 3). Of the 14 patients
with available information on attributable death, 10
(71.4%) died due to infection (Supplementary Table 3),
all of which had disseminated disease, eight with con-
firmed blood stream infection.
Day 42 mortality was 59% in immunocompromised
patients and 17.6% in immunocompetent patients
(Fisher’s Exact Test p¼ 0.004). In patients with underly-
ing malignancy, day 42 mortality was 71.4%, 90% of
those had confirmed fungemia. Overall mortality and
day 42 mortality in patients with disseminated disease
was higher in all risk groups compared to the localized
infection (Table 3).
Mean survival time in immunocompromised patients
was 114 days (CI 95% 66–163) (Supplementary Figure
2(B)), in patients with blood stream infection 22 days (CI
95% 9–37). Mean survival time of patients with underly-
ing malignancy and SOT was 63 days (CI 95% 21–105)
and 242 days (CI 95% 127–357), respectively.
Immunocompetent patients had a mean survival time
of 302 days (CI 95% 239–367).
In patients with malignancy, disseminated disease
was associated with a worse outcome and surgical
intervention as antifungal treatment was associated
with improved outcome overall (Supplementary Table
4(B)). Of five patients with eye infection who were not
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surgically treated, all died within 49 days, 4 had funge-
mia. Of seven patients with surgically treated eye infec-
tion, one patient with fungemia died after three weeks
and six patients were alive with median follow up time
of 180 days.
Overall mortality was lower in patients who received
voriconazole for treatment compared to other antifun-
gals (52.6% versus 68.8%, Fisher’s Exact Test p¼ 0.37)
(Supplementary Figure 3(B)). Treatment with voricon-
azole together with terbinafine was not associated with
improved day 42 and overall survival in patients with
lomentosporiosis compared to treatment with voricon-
azole without terbinafine overall and in any of the
tested subgroups (e.g. blood stream infection and local-
ized disease, HSCT and no HSCT, all immunocomprom-
ised and all immunocompetent patients). Overall
mortality was similar in patients treated with voricon-
azole and patients treated with voriconazole and ter-
binafine (50% and 55.3%, Chi2 p¼ 0.757).
Antifungal susceptibility
In vitro susceptibility to antifungals were available for
18 clinical isolates from different patients (Table 4).
Median MIC were low for olorofim (0.0039mg/L for all
isolates). For all other antifungals tested, median MIC
was 8mg/L or higher. Occasionally isolates show MIC of
1mg/L or lower for echinocandins, amphotericin B or
voriconazole. Other than these, MICs were at least
4mg/L for all antifungals in all isolates tested.
Discussion
Scedosporium spp. and L. prolificans infections are rare
diseases as reflected by their reported frequency.
Through literature search and in FungiScopeVR we iden-
tified 264 individual cases of severe IFD caused by
Scedosporium spp. or L. prolificans that were diagnosed
between 2000 and 2017. This translates to an average
of only 16 reported cases per year. This may be due to
a diagnostic and a reporting bias, and thus not reflect
true epidemiology. Overall, Scedosporium spp. and L.
prolificans infections account for less than 1% of all
mold infections (Caira et al. 2008), and affect less than 1
in 60 000 in-patients in general (M€ugge and Sch€omig
2017). Regional differences in incidences, such as seen
with the relatively high incidence of these infections in
Australia compared to other countries, may be due to
climatic and environmental conditions that favour
growth of the fungi. Soil pH has been suggested to
play a role (Kaltseis et al. 2009). Similar pH ranges of
the soil as in Australia are found in Mid East USA and
Canada, Eastern South-America, Southern Europe,
North and South Africa, and Mid and Central Asia
(Global Soil Data Task 2014). Reported cases were pre-
dominately from those regions. Most Scedosporium spp.
infections were reported in patients after organ trans-
plantation, whereas L. prolificans infections were mostly
diagnosed in patients with an underlying malignancy.
Effective prophylaxis is particularly difficult in the case
of L. prolificans, due to pan-resistance to virtually all sys-
temically active antifungal agents currently available.
Thus, incidence of break-through infections in haemato-
logical patients receiving posaconazole or voriconazole
as first line antifungal prophylaxis is likely to be higher
for L. prolificans than for Scedosporium spp.
Clinical manifestation differed between scedosporio-
sis and lomentosporiosis as well as between patient
populations. Infection with Scedosporium spp. fre-
quently disseminates to distant organs, often to the
CNS even in immunocompetent patients, without pri-
mary bloodstream infection. L. prolificans infection
often presents as fungemia, while brain infections are
reported less commonly (Horre et al. 2000; Mellinghoff
et al. 2002). Tropism for blood vessels and haematogen-
ous spread is considerable in both diseases (Kowacs
et al. 2004). Disseminated disease is independently
associated with worse outcome, fungemia being the
key determinant. In our dataset, fungemia proved fatal
in all immunocompromised patients and in all but one
immunocompetent patients.
Infection of the CNS was found to be associated with
worse outcome in SOT patients with Scedosporium spp.
infection. The true impact of brain infection on survival,
also in other risk groups, is difficult to assess. Several
aspects need to be considered. Despite CNS being
reported as the sole site of infection for several
patients, in the absence of previous brain injury or sur-
gery, it is highly unlikely to be the primary site (O’Bryan
2005). If not all potentially infected sites are examined
thoroughly, the additional impact of brain infection
may be underestimated. On the contrary, CNS infec-
tions may not be identified before death. Reasons are
manifold, involvement of the CNS is not suspected,
patient’s condition does not allow transport to radi-
ology or invasive diagnostic procedures, imaging find-
ings may be inconclusive, or results from
microbiological workup may remain negative. With
fewer autopsies being performed nowadays, brain
infections may not be reported altogether (Tietz et al.
2005). Due to low susceptibility of the fungus and low
permeability of the blood-brain barrier for many anti-
fungal drugs, it is undisputed that CNS infection is
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particularly difficult to treat, and mortality is high
(Kantarcioglu et al. 2008).
With voriconazole, known for its ability to cross the
blood-brain barrier, an antifungal became available for
successful treatment of brain lesions (Schwartz et al.
2005). Voriconazole showed high in vitro activity against
S. apiospermum isolates (Meletiadis et al. 2002). Current
guidelines recommend the use of voriconazole along
with surgical resection (Tortorano et al. 2014). A com-
prehensive study on treatment efficacy in 107 scedo-
sporiosis patients treated with voriconazole showed
successful response in 57% of patients overall (Troke
et al. 2008). In our analysis, day 42 and overall mortality
was numerically lower in immunocompromised
patients with scedosporiosis and lomentosporiosis
treated with voriconazole compared to those treated
with amphotericin B. Differences between voriconazole
alone or in combination with amphotericin B were not
seen. Combination therapies are widely used to exploit
synergistic effects. Terbinafine for example, although
demonstrating limited in vitro activity alone, showed
synergy in combination with azoles in several in vitro
studies (Ryder and Leitner 2001; Meletiadis et al. 2003).
The additional value of terbinafine in combination
treatment of patients with mold infections is controver-
sial. Poor tissue penetration of terbinafine casts doubt
on the clinical meaning of such synergy. Our analysis
did not identify synergy of terbinafine. Olorofim is a
new antifungal agent that shows promising antifungal
activity in vitro. In our analysis, olorofim had low MICs
against all Scedosporium spp. and L. prolificans strains,
confirming recently published results (Wiederhold et al.
2017; Biswas et al. 2018). A clinical efficacy study on
olorofim is upcoming. Similarly, APX001 (E1210) a novel
antifungal agent that disrupts fungal cell wall assembly,
showed good in vitro activity against Scedosporium
spp. and L. prolificans and is currently tested in
phase I clinical trial in patients with acute leukaemia
(clinicaltrials.gov 2017; Castanheira et al. 2012).
Route of entry of Scedosporium spp. and L. prolificans
is frequently through the respiratory tract, which
explains the high incidence of lung lesions. In this case
series, lung involvement predicted worse outcome of
scedosporiosis in patients with malignancy in univariate
analysis. Furthermore, disseminated infection was asso-
ciated with worse outcome in patients with
Scedosporium spp. infection post SOT and in patients
with L. prolificans infection and malignancy. In our ana-
lysis, we did not identify additional potentially import-
ant predictors. Proper control of confounders is difficult
due to heterogeneity of hosts and diverse clinical pat-
terns of IFD, leaving us with small numbers not
allowing multivariate analysis. Trends determined in
univariate analysis need further confirmation in a
larger dataset.
Infections caused by Scedosporium spp. and L. pro-
lificans resemble other mold infections on cytological
and histological examination, challenging timely diag-
nosis and targeted treatment (Guarro et al. 2006).
High virulence of certain species, in particular L. pro-
lificans, and less predictable susceptibility patterns
urge for prompt pathogen identification. We
detected low voriconazole MICs and slightly higher
MICs for itraconazole and posaconazole in most
Scedosporium spp. strains. In comparison, for L. prolif-
icans MICs were higher for all antifungals and low
voriconazole MICs were determined in individual
cases only. Amphotericin B or echinocandin MICs
were low in few Scedosporium spp. strains, which
may offer a treatment option in respective patients.
Supportive experimental in vivo data are scarce with
varying results on efficacy of single and combination
therapy with amphotericin B or echinocandins
(Rodriguez et al. 2009; Lackner et al. 2014). The clin-
ical predictive value of in vitro susceptibility of
amphotericin B or echinocandins and thus, the add-
itional therapeutic benefit for patients is
still unknown.
Successful treatment of L. prolificans infections seems
almost impossible. Currently available antifungals are
ineffective against the vast majority of strains and surgi-
cal treatment is rarely an option due to the poor general
condition of most patients and because disease
presents as fungemia or complex disseminated disease
in most cases. Thus, most patients are left with virtually
no treatment option. This dilemma is clearly reflected
by the high mortality rates in these patients and short
survival time compared to Scedosporium spp. infections.
Despite being a feasible approach to comprehen-
sively investigate the epidemiology and treatment pat-
terns of these rare diseases, this study has obvious
limitations. Due to recent changes in the taxonomy of
Scedosporium and various standards in mycological
diagnostics in different countries, reported species may
or may not be correctly identified. Furthermore, one
cannot be certain on the correct diagnosis of an inva-
sive infection, due to lack of data in some cases.
Predisposing host factors are sometimes difficult to
assess, hampered by the frequently rapid deterioration
of the fungal infection until death. Thus, impaired
immune system may not have been recognized and
patients may have been wrongly deemed immunocom-
petent. Nonetheless, Scedosporium spp. and L. prolifi-
cans infections have been reported in several
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immunocompetent patients with devastating outcome.
Through direct wound inoculation potentially everyone
is at risk for invasive fungal infections.
Infections caused by Scedosporium spp. and L. prolifi-
cans are extremely rare and patient populations at risk
are diverse. CNS involvement, disseminated disease,
and immunosuppression determine prognosis. During
clinical management and eventually clinical trial design,
these factors should be considered.
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